ASPA

Across TCGA pan-cancer cohorts, ASPA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ASPA data layer compared with 27 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ASPA mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ASPA expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where ASPA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.572	0.265	<.001	72	view →
CCRCC	DFS	Tertile	III,IV	0.742	0.224	<.001	46	view →
GBM	OS	Median	All	0.733	0.984	.002	21	view →
HNSC	DFS	Tertile	All	0.885	1.000	.001	15	view →
UCEC	OS	Tertile	II,III,IV	0.568	1.000	.020	8	view →
LUAD	DFS	Median	II,III,IV	0.642	0.991	<.001	7	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ASPA–PDAC (OS)

Open the PDAC breakdown →